Literature DB >> 15383578

Ikaros null mice display defects in T cell selection and CD4 versus CD8 lineage decisions.

Julie A Urban1, Susan Winandy.   

Abstract

Previous evidence suggested that the hemopoietic-specific nuclear factor Ikaros regulates TCR signaling thresholds in mature T cells. In this study, we test the hypothesis that Ikaros also sets TCR signaling thresholds to regulate selection events and CD4 vs CD8 lineage determination in developing thymocytes. Ikaros null mice were crossed to three lines of TCR-transgenic mice, and positive selection, negative selection, and CD4 vs CD8 lineage decisions were analyzed. Mice expressing a polyclonal repertoire or a MHC class II-restricted TCR transgene exhibited enhanced positive selection toward the CD4 lineage. Moreover, in the absence of Ikaros, CD4 development can occur with decreased thresholds of TCR signaling. In addition, CD4 single-positive thymocytes were detected in MHC class I-restricted TCR-transgenic Ikaros null mice. To assess the role of Ikaros in negative selection, we analyzed deletion of T cells induced by conventional Ag or by endogenous superantigen. Surprisingly, negative selection was impaired in Ikaros null thymocytes despite evidence of high levels of TCR signal and no intrinsic defect in apoptosis ex vivo. To our knowledge, these data identify Ikaros as the first nuclear factor that plays a critical role in regulating negative selection as well as CD4 vs CD8 lineage decisions during positive selection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383578     DOI: 10.4049/jimmunol.173.7.4470

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Ikaros is required to survive positive selection and to maintain clonal diversity during T-cell development in the thymus.

Authors:  Kevin W Tinsley; Changwan Hong; Megan A Luckey; Joo-Young Park; Grace Y Kim; Hee-Won Yoon; Hilary R Keller; Andrew J Sacks; Lionel Feigenbaum; Jung-Hyun Park
Journal:  Blood       Date:  2013-08-01       Impact factor: 22.113

2.  Ikaros sets the potential for Th17 lineage gene expression through effects on chromatin state in early T cell development.

Authors:  Larry Y Wong; Julianne K Hatfield; Melissa A Brown
Journal:  J Biol Chem       Date:  2013-10-21       Impact factor: 5.157

3.  Ikaros' suspended flight in the thymus.

Authors:  Naomi Taylor; Valérie S Zimmermann
Journal:  Blood       Date:  2013-10-03       Impact factor: 22.113

Review 4.  Lineage fate and intense debate: myths, models and mechanisms of CD4- versus CD8-lineage choice.

Authors:  Alfred Singer; Stanley Adoro; Jung-Hyun Park
Journal:  Nat Rev Immunol       Date:  2008-10       Impact factor: 53.106

5.  Ikaros in B cell development and function.

Authors:  Maclean Sellars; Philippe Kastner; Susan Chan
Journal:  World J Biol Chem       Date:  2011-06-26

6.  Expression patterns of Ikaros family members during positive selection and lineage commitment of human thymocytes.

Authors:  Julie L Mitchell; Amara Seng; Thomas M Yankee
Journal:  Immunology       Date:  2016-09-20       Impact factor: 7.397

Review 7.  Transcriptional repressors, corepressors and chromatin modifying enzymes in T cell development.

Authors:  Michael J Shapiro; Virginia Smith Shapiro
Journal:  Cytokine       Date:  2010-12-16       Impact factor: 3.861

8.  Cutting Edge: Ikaros null thymocytes mature into the CD4 lineage with reduced TCR signal: A study using CD3{zeta} immunoreceptor tyrosine-based activation motif transgenic mice.

Authors:  Julie A Urban; William Brugmann; Susan Winandy
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

9.  Ikaros directly represses the notch target gene Hes1 in a leukemia T cell line: implications for CD4 regulation.

Authors:  Katie L Kathrein; Sheila Chari; Susan Winandy
Journal:  J Biol Chem       Date:  2008-02-20       Impact factor: 5.157

10.  Ikaros regulates Notch target gene expression in developing thymocytes.

Authors:  Sheila Chari; Susan Winandy
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.